Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/34654

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34654

Title:	Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
Authors:	Lee, Mei-Chuan Hua, Yi-Ming Yang, Chun-Ting Kuo, Fang-Hsiu Chang, Wei-Ting Tang, Hsin-Ju Toh, Han Siong Lin, Yu-Min Chen, Sih-Yao Chang, Hung-Yu Liao, Chia-Te
Contributors:	Chi Mei Hospital National Cheng Kung University National Cheng Kung University Chi Mei Hospital National Cheng Kung University Southern Taiwan University of Science & Technology Chang Gung University of Science & Technology Chi Mei Hospital Department of Health and Nutrition, Chia Nan University of Pharmacy & Science National Yang Ming Chiao Tung University Cheng Hsin General Hospital
Keywords:	cotransporter 2 inhibitors empagliflozin risk
Date:	2022
Issue Date:	2023-12-11 14:03:09 (UTC+8)
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Abstract:	Background:Some sodium-glucose co-transporter-2 (SGLT2) inhibitors showed benefits on heart failure (HF), but different SGLT2/SGLT1 selectivity might influence the treatment effect. This study aimed to meta-analyze the treatment effects of SGLT2 inhibitors and the diversity of receptor selectivity for patients with and without HF. Methods:Randomized controlled trials were searched in PubMed, Embase, Cochrane databases and ClinicalTrials.gov registry from inception to October 2020. The interest outcomes were analyzed with random-effects models and presented with a risk ratio (RR) and 95% confidence interval (CI). Subgroup analyses examined the treatment effects among SGLT2 inhibitors with different SGLT2/SGLT1 selectivity. Results:The final analyses included 10 trials and 52,607 patients. The RR of total cardiovascular (CV) death or hospitalization for HF (HHF) between SGLT2 inhibitors and placebo was 0.79 (95% CI 0.74-0.84, I-2 = 31%). With SGLT2 inhibitors, HF patients had reduced mortality risks (RR 0.89, 95% CI 0.80-0.99, I-2 = 0), and non-HF patients had lower risks of major adverse CV events (RR 0.92, 95% CI 0.85-0.99, I-2 = 0). The risk reduction of HHF was consistent in groups of HF (RR 0.72, 95% CI 0.64-0.80, I-2 = 8%) and non-HF (RR 0.74, 95% CI 0.61-0.89, I-2 = 0), but the effect of the low SGLT2/SGLT1 selectivity inhibitor was insignificant in non-HF patients. Conclusion:The efficacy of SGLT2 inhibitors on risk reduction of total CV death or HHF is consistent with the previous studies. The regimen is beneficial for reducing mortality in patients with HF and major adverse CV events in those without HF. Different SGLT2/SGLT1 selectivity may differ in the treatment effects in patients with and without HF.
Relation:	MEDICINE, v.101, n.51, e32489
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	97	View/Open
MD.0000000000032489.pdf		1555Kb	Adobe PDF	49	View/Open

Loading...